Clinical trials: pCR Rate
COVID-19
COVID-19 Infection Control Using H2O2 Mouth Wash and Nasal Spray
Hydrogen peroxide is produced physiologically by oral bacteria and plays a significant role in the balance of oral microecology since it is an important antimicrobial agent.
- Trial name
- NCT04878042
- Testing
- Hydrogen peroxide
- Where
- Italy
- Volunteers
- healthy volunteers welcome
- Sponsor
- EPISTATA
Breast Cancer, Neoadjuvant Chemotherapy
Comparison of pCR Rate After Neadjuvant Chemotherapy Guided by Result of in Vitro Cell Culture Drug Sensitivity or Physician's Choice
Neoadjuvant chemotherapy is an important treatment for breast cancer patients. Patients with triple negative or Her2 enriched subtype who achieved pCR after neoadjuvant chemotherapy would have longer survival.
- Conditions
- Breast Cancer, Neoadjuvant Chemotherapy, Drug Effect
- Trial name
- NCT04130750
- Testing
- treatment of drug screening
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University People's Hospital
Prostate Cancer
Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)
This study evaluates the use of chemotherapy with cabazitaxel in addition to abiraterone acetate, prednisone, and leuprolide in neoadjuvant setting prior to radical prostatectomy in patients with high-risk prostate carcinoma.
- Trial name
- ACDC-RP (NCT02543255)
- Testing
- Abiraterone acetate with prednisone, Leuprolide, Cabazitaxel with peg-filgrastim
- Where
- 5 sites in Canada
- Volunteers
- 76 people
- Sponsor
- University Health Network, Toronto
COVID-19
Study of the Effect of Systematic Screening of Residents and Caregivers With Covid-19 by Nasopharyngeal Swab (RT-PCR)
The current COVID-19 epidemic has overwhelmed the health systems of many countries in which it has broken out, forcing various governments to institute population containment measures.
- Trial name
- INMESO-Covid (NCT05085522)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Chronic Hepatitis B, Roadmap Concept in Chronic Hepatitis B Treatment
Efficacy Study of Telbivudine in Chronic Hepatitis B Patients
This study is designed to support the optimal use of telbivudine by providing data to refine our understanding of telbivudine efficacy and resistance in real life clinical setting in patients with chronic hepatitis B with defined…
- Conditions
- Chronic Hepatitis B, Roadmap Concept in Chronic Hepatitis B Treatment, 24-week PCR Negativity of Telbivudine, PCR Negativity at 52 and 104 Week
- Trial name
- NCT01958229
- Where
- Taiwan
- Volunteers
- 23 people
- Sponsor
- National Taiwan University Hospital
SARS-CoV-2, Coronavirus Infection
Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds
To create a protocol for treatment of Pakistani patients with SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in…
- Conditions
- SARS-CoV-2, Coronavirus Infection, Asymptomatic Condition, COVID-19
- Trial name
- PEACE (NCT04346667)
- Testing
- Hydroxychloroquine Sulfate Regular dose, Hydroxychloroquine Sulfate Loading Dose, Chloroquine
- Where
- 3 sites in Pakistan
- Volunteers
- 125 people
- Sponsor
- Government of Punjab, Specialized Healthcare and Medical Education Department
Breast Neoplasms
Association Between HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving Neoadjuvant Endocrine or Chemotherapy
In estrogen receptor (ER)-positive breast cancer (BC), human epidermal growth factor receptor-2 (HER2)-low ones are reported to have distinct clinical and molecular features from those with HER2-zero or HER2-positive status.
- Trial name
- NCT05673850
- Testing
- NET or NCT
- Where
- China
- Volunteers
- 518 people
- Sponsor
- Peking University
Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy
Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
This study aims to investigate the efficacy and safety of neoadjuvant cadonilimab in combination with perioperative SOX chemotherapy, compared to perioperative SOX chemotherapy alone, in patients with diffuse or mixed-type…
- Conditions
- Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate
- Trial name
- NCT06949033
- Testing
- Neoadjuvant cadonilimab combined with perioperative SOX
- Where
- 4 sites in China
- Volunteers
- 668 people
- Sponsor
- Zuoyi Jiao
Pathological Complete Remission, Objective Response Rate
Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma
This study is a prospective, single-arm, phase II exploratory clinical trial. The primary endpoint of this study is to evaluate the pathological complete response (pCR) rate after surgery and to assess the safety of neoadjuvant…
- Conditions
- Pathological Complete Remission, Objective Response Rate, Immune-related Adverse Events, Quality of Life
- Trial name
- NCT07430579
- Testing
- adebrelimab combined with chemotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The Second Hospital of Shandong University
Breast Adenocarcinoma
Assessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemotherapy
The goal of this clinical trial is to assess whether the addition of preoperative stereotactic body radiation therapy (SBRT) can improve pathological complete response (pCR) rates and safety in breast cancer patients who do not…
- Trial name
- NCT06596018
- Testing
- SBRT, Chemotherapy
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy
Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
This study aims to compare the efficacy and safety of neoadjuvant apatinib combined with sintilimab and perioperative SOX chemotherapy versus neoadjuvant sintilimab combined with perioperative SOX chemotherapy in locally advanced…
- Conditions
- Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate
- Trial name
- NCT06925243
- Testing
- Neoadjuvant apatinib combined with sintilimab and perioperative SOX, Neoadjuvant sintilimab combined with perioperative SOX
- Where
- 4 sites in China
- Volunteers
- 682 people
- Sponsor
- Zuoyi Jiao
Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer
This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment
This study was a prospective, one-arm open phase II clinical trial. A systematic review of the pCR of apatinib in combination with the albumin paclitaxel and carboplatin regimens for the neoadjuvant therapy of triple-negative…
- Trial name
- NCT03650738
- Testing
- Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Triple-negative Breast Cancer
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
We plan to explore the efficacy and safety of albumin-bound paclitaxel+carboplatin+Camrelizumab in neoadjuvant therapy for early TNBC patients, optimize the administration method and drug combination therapy.
- Trial name
- NCT06817525
- Testing
- 6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1), 6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1)
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Henan Cancer Hospital
Sars-CoV2, Symptomatic Condition
PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds
To treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroquine and hydroxychloroquine…
- Conditions
- Sars-CoV2, Symptomatic Condition, Covid-19
- Trial name
- PRECISE (NCT04351191)
- Testing
- Hydroxychloroquine Sulfate Regular dose, Hydroxychloroquine Sulfate Loading Dose, Chloroquine
- Where
- 4 sites in Pakistan
- Volunteers
- 137 people
- Sponsor
- Government of Punjab, Specialized Healthcare and Medical Education Department
Urinary Tract Infections
Morbidity Rate for UTI Through Use of PCR-Based Diagnosis and Management
This retrospective study is to determine if the use of PCR for detection and identification of pathogens in UTI along with antimicrobial susceptibility information, affords more efficacious treatment of UTI, as compared to…
- Trial name
- NCT04108910
- Testing
- Guidance UTI
- Volunteers
- 66,381 people
- Sponsor
- Pathnostics
Breast Cancer
A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
This 4 arm study will evaluate the efficacy and safety of 4 neoadjuvant treatment regimens in female patients with locally advanced, inflammatory or early stage HER2 positive breast cancer.
- Trial name
- NCT00545688
- Testing
- Herceptin, Docetaxel, Pertuzumab
- Where
- 77 sites in Australia, Austria and 16 more
- Volunteers
- 417 people
- Sponsor
- Hoffmann-La Roche
Sars-CoV2
LILLE COVID RESEARCH NETWORK (Covid-19)
The Lille University Hospital developped a research objective common to all the services which took care of patients, "suspected patient", "possible case", "probable case" or "confirmed case" infected with SARS-CoV-2 by…
- Trial name
- LICORNE (NCT04475211)
- Where
- France
- Volunteers
- 757 people
- Sponsor
- University Hospital, Lille
Rectal Cancer
Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen
This study is designed to test the efficacy and safety of Total Neoadjuvant Treatment plus SHR1210（an anti-PD-1 Inhibitor) for High-risk locally advanced Rectal Cancer, Meanwhile, screening effective Biomarker base on neoantigen.
- Trial name
- NCT04340401
- Testing
- SHR-1210, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking University Cancer Hospital & Institute
Triple Negative Breast Cancer, Vitamin D Deficiency
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
A two arm pilot study investigating the rate of pathologic complete response in patients with vitamin D deficiency and triple negative breast cancer undergoing standard neoadjuvant chemotherapy + vitamin D supplementation…
- Conditions
- Triple Negative Breast Cancer, Vitamin D Deficiency, Invasive Breast Cancer
- Trial name
- NCT04677816
- Testing
- Standard of Care Neoadjuvant Chemotherapy (NAC), Vitamin D3, Drug Diary
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Wake Forest University Health Sciences
Chronic Myelocytic Leukemia
Evaluating True PCR-negative Rate of Frontline Dasatinib in Early Chronic Phase CML for Therapeutic Harmonization
This study is designed to confirm the efficacy of dasatinib 100mg once daily in producing a complete molecular response and to prove a possibility of "Operational Cure" in CMR patients.
- Trial name
- NCT02975115
- Testing
- RQ-PCR RNA Analysis
- Volunteers
- 102 people
- Sponsor
- Seoul St. Mary's Hospital